Phosphate Binding Therapy to Lower Serum Fibroblast-Growth-Factor-23 Concentrations in Chronic Kidney Disease: Rationale and Study Design of the Sevelamer on FGF23 Trial (SoFT)

Aaltje Y. Adema, Maarten A. de Jong, Martin H. de Borst, Pieter M. ter Wee, Marc G. Vervloet

Research output: Contribution to journalArticleProfessional

6 Citations (Scopus)
Original languageEnglish
Pages (from-to)215-220
JournalNEPHRON
Volume134
Issue number4
DOIs
Publication statusPublished - 2016

Keywords

  • Chronic kidney disease
  • Fibroblast growth factor-23
  • Phosphate binding therapy
  • Sevelamer
  • Sevelamer on FGF23 trial
  • SoFT

Cite this